logo

For the Inventor, By the Inventor

Semaphore, Australia

Jorgen Alvar Mould

This inventor holds 6 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignees: Bionomics Inc., Merck Patent Gmbh. Active years: 2012-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jorgen Alvar Mould. Retrieved from https://idiyas.com/inventor/jorgen-alvar-mould

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 6 

 

Average Co-Inventor Count = 8.7

ph-index = 1

Forward Citations = 3(Granted Patents)


Location History:

  • Exeter, AU (2012)
  • Semaphore, AU (2012 - 2013)
  • Semaphore South, AU (2016 - 2018)

Company Filing History:

goldMedal6 out of 64 
 
Bionomics Inc.
 patents
silverMedal2 out of 3,022 
 
Merck Patent Gmbh
 patents
where one patent can have more than one assignee

Years Active: 2012-2018

Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents
1. 9914702 - Amine derivatives as potassium channel blockers (2018-03-13),
2. 9493451 - Amine derivatives as potassium channel blockers (2016-11-15),
3. 8507539 - Potassium channel blockers and uses thereof (2013-08-13),
4. 8309545 - Benzofuran potassium channel blockers and uses thereof (2012-11-13),
5. 8217189 - Chromenone potassium channel blockers and uses thereof (2012-07-10),
6. 8202513 - Aryl potassium channel blockers and uses thereof (2012-06-19),

Title: Jorgen Alvar Mould: Innovator in Potassium Channel Modulation

Introduction

Jorgen Alvar Mould is a notable inventor based in Semaphore, Australia. He has made significant contributions to the field of pharmaceutical sciences, particularly in the modulation of potassium channels. With a total of 6 patents to his name, Mould's work has implications for the treatment of various autoimmune and inflammatory diseases.

Latest Patents

One of Mould's latest patents focuses on "Amine derivatives as potassium channel blockers." This invention relates to compounds that are useful in modulating potassium channel activity in cells, specifically targeting Kv1.3 channels found in T cells. The invention also discusses the application of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis. Additionally, it covers pharmaceutical compositions containing these compounds and methods for their preparation.

Career Highlights

Throughout his career, Jorgen Alvar Mould has worked with prominent companies such as Bionomics Inc. and Merck Patent GmbH. His experience in these organizations has allowed him to develop innovative solutions that address critical health issues.

Collaborations

Mould has collaborated with notable professionals in his field, including Andrew John Harvey and Dharam Paul. These partnerships have contributed to the advancement of his research and the successful development of his patents.

Conclusion

Jorgen Alvar Mould is a distinguished inventor whose work in potassium channel modulation has the potential to impact the treatment of autoimmune and inflammatory diseases. His contributions to the field are significant and continue to inspire further research and innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…